A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

New research is taking a closer look at what can happen when people stop taking GLP-1 medications for a long period of time.

The small study, published recently in the journal Obesity, looked at 34 patients who had already lost weight on GLP-1 ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. But injectable medications aren’t right for everyone. That’s where a new wave of oral GLP-1 ...

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.

Research led by Penn Dental's Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as ...

In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.

SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...